Company intelligence / Profile preview

Genosera

Ownership: Private
Development stage: Preclinical

Overview

Genosera is developing next-generation bicistronic AAV-based gene therapies for rare genetic muscle and metabolic diseases. All pipeline programs are currently in preclinical development. The company’s lead program targets GNE myopathy with a novel two-gene approach designed to both halt progression and reverse existing muscle damage. No clinical results have been reported yet.

Therapeutic areas: Metabolic DisordersRare DiseasesNeurology
Modalities: Gene therapyAdeno-associated virus (AAV) gene therapyBicistronic gene therapy (two-gene AAV)
Industry: Biotech

Drug pipeline

6 assets

GA-002

Preclinical

5 more assets in the full pipeline.

Partnerships

Solve GNE LLC – sponsored research agreement to develop bicistronic AAV treatment for GNE Myopathy/HIBM

Beyond the preview

Go deeper on Genosera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genosera.